Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Other Accumulated Expenses (2016 - 2025)

Haemonetics (HAE) has 16 years of Other Accumulated Expenses data on record, last reported at $134.3 million in Q4 2025.

  • For Q4 2025, Other Accumulated Expenses fell 3.52% year-over-year to $134.3 million; the TTM value through Dec 2025 reached $134.3 million, down 3.52%, while the annual FY2025 figure was $148.1 million, 8.85% up from the prior year.
  • Other Accumulated Expenses reached $134.3 million in Q4 2025 per HAE's latest filing, roughly flat from $134.0 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $150.0 million in Q3 2024 and bottomed at $85.3 million in Q3 2022.
  • Average Other Accumulated Expenses over 5 years is $125.9 million, with a median of $130.1 million recorded in 2021.
  • Peak YoY movement for Other Accumulated Expenses: skyrocketed 41.93% in 2021, then plummeted 33.26% in 2022.
  • A 5-year view of Other Accumulated Expenses shows it stood at $119.7 million in 2021, then dropped by 15.63% to $101.0 million in 2022, then soared by 31.12% to $132.4 million in 2023, then rose by 5.15% to $139.2 million in 2024, then fell by 3.52% to $134.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $134.3 million in Q4 2025, $134.0 million in Q3 2025, and $145.6 million in Q2 2025.